IL283687A - usp19 inhibitors and their use for therapeutic purposes - Google Patents
usp19 inhibitors and their use for therapeutic purposesInfo
- Publication number
- IL283687A IL283687A IL283687A IL28368721A IL283687A IL 283687 A IL283687 A IL 283687A IL 283687 A IL283687 A IL 283687A IL 28368721 A IL28368721 A IL 28368721A IL 283687 A IL283687 A IL 283687A
- Authority
- IL
- Israel
- Prior art keywords
- therapy
- usp19
- inhibitors
- usp19 inhibitors
- Prior art date
Links
- 101150006083 USP19 gene Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1819936.4A GB201819936D0 (en) | 2018-12-06 | 2018-12-06 | Therapeutic methods |
| GBGB1904341.3A GB201904341D0 (en) | 2019-03-28 | 2019-03-28 | Therapeutic methods |
| PCT/GB2019/053456 WO2020115500A1 (en) | 2018-12-06 | 2019-12-06 | Usp19 inhibitors for use in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL283687A true IL283687A (en) | 2021-07-29 |
Family
ID=68887434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL283687A IL283687A (en) | 2018-12-06 | 2021-06-03 | usp19 inhibitors and their use for therapeutic purposes |
Country Status (12)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3134564A1 (en) * | 2019-05-06 | 2020-11-12 | Lawrence Marcin | Inhibiting usp19 |
| GB202104097D0 (en) * | 2021-03-24 | 2021-05-05 | Almac Discovery Ltd | Pharmaceutical compounds |
| GB202311227D0 (en) | 2023-07-21 | 2023-09-06 | Almac Discovery Ltd | Pharmaceutical compounds |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPO111096A0 (en) * | 1996-07-18 | 1996-08-08 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
| WO2009072643A1 (en) | 2007-12-03 | 2009-06-11 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound and use thereof |
| CN104174021A (zh) * | 2013-05-22 | 2014-12-03 | 复旦大学附属华山医院 | 蛋白酶体抑制剂在制备治疗慢性低度炎症性疾病药物中的用途 |
| TWI698436B (zh) * | 2014-12-30 | 2020-07-11 | 美商佛瑪治療公司 | 作為泛素特異性蛋白酶7抑制劑之吡咯并及吡唑并嘧啶 |
| GB201612938D0 (en) * | 2016-07-26 | 2016-09-07 | Almac Discovery Ltd | Pharmaceutical compounds |
| AU2018342089B2 (en) * | 2017-09-26 | 2024-07-11 | Dana-Farber Cancer Institute, Inc. | Novel USP7 inhibitors for treating multiple myeloma |
| GB201801562D0 (en) * | 2018-01-31 | 2018-03-14 | Almac Diagnostics Ltd | Pharmaceutical compounds |
-
2019
- 2019-12-06 JP JP2021532119A patent/JP2022510700A/ja active Pending
- 2019-12-06 CN CN201980091404.7A patent/CN113395965A/zh active Pending
- 2019-12-06 AU AU2019393161A patent/AU2019393161A1/en not_active Abandoned
- 2019-12-06 KR KR1020217019978A patent/KR20210100127A/ko not_active Withdrawn
- 2019-12-06 SG SG11202105911PA patent/SG11202105911PA/en unknown
- 2019-12-06 CA CA3121422A patent/CA3121422A1/en active Pending
- 2019-12-06 MX MX2021006542A patent/MX2021006542A/es unknown
- 2019-12-06 EP EP19821175.7A patent/EP3890737B1/en active Active
- 2019-12-06 US US17/299,971 patent/US20220016115A1/en not_active Abandoned
- 2019-12-06 BR BR112021010645-6A patent/BR112021010645A2/pt not_active IP Right Cessation
- 2019-12-06 WO PCT/GB2019/053456 patent/WO2020115500A1/en not_active Ceased
-
2021
- 2021-06-03 IL IL283687A patent/IL283687A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020115500A1 (en) | 2020-06-11 |
| AU2019393161A1 (en) | 2021-06-17 |
| EP3890737A1 (en) | 2021-10-13 |
| EP3890737B1 (en) | 2024-06-05 |
| CA3121422A1 (en) | 2020-06-11 |
| MX2021006542A (es) | 2021-07-07 |
| BR112021010645A2 (pt) | 2021-08-17 |
| KR20210100127A (ko) | 2021-08-13 |
| US20220016115A1 (en) | 2022-01-20 |
| CN113395965A (zh) | 2021-09-14 |
| SG11202105911PA (en) | 2021-07-29 |
| JP2022510700A (ja) | 2022-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202105747XA (en) | Csf1r inhibitors for use in treating cancer | |
| SG11202104356VA (en) | Bt1718 for use in treating cancer | |
| IL269462B (en) | mdm2 inhibitors and therapeutic methods using them | |
| SG10201913331VA (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| IL282350A (en) | Bernani-RGMC inhibitors and their use | |
| IL251618A0 (en) | Combined treatment including ox40 binding agonists and tigit inhibitors | |
| SI3806898T1 (sl) | Antagonist Gremlin-1 za uporabo pri zdravljenju raka | |
| HUE070659T2 (hu) | KDM1A inhibitor és annak felhasználása terápiában | |
| GB201702160D0 (en) | Inhibitors for use in therapy | |
| EP3313514A4 (en) | POSITIONING DEVICE FOR USE IN THERAPEUTIC TREATMENT | |
| HUE068702T2 (hu) | Konjugált antiszensz vegyületek terápiában való alkalmazásra | |
| IL284053A (en) | New compounds and their use in therapy | |
| IL288728A (en) | Anti-sortilin antibodies for use in therapy | |
| ZA202007955B (en) | Ccr5 inhibitor for use in treating cancer | |
| ZA202000904B (en) | Mpo inhibitors for use in medicine | |
| PL3293201T3 (pl) | Łączenie adenowirusa i inhibitorów punktów kontrolnych do leczenia nowotworu | |
| IL255530A (en) | Efflux-pump inhibitors and therapeutic uses thereof | |
| ZA202006886B (en) | R-fadrozole for use in the treatment of aldostonerism | |
| GB201821147D0 (en) | Mirna for use in therapy | |
| GB201615844D0 (en) | Agents for use in therapy | |
| EP4670683A3 (en) | SURGICAL APPARATUS | |
| HK40052012A (en) | Usp19 inhibitors for use in therapy | |
| GB201908884D0 (en) | Inhibitors and use | |
| GB2578008B (en) | 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment | |
| GB201503053D0 (en) | Apparatus for use in magnetic hyperthermia treatments |